aic316 mesylate hydrate

Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (IC50: 0.02 μM against HSV1-2). Pritelivir mesylate hydrate is an inhibitor of the viral helicase-primase complex. Pritelivir mesylate hydrate shows antiviral activity in vit

Garenoxacin mesylate hydrate (Garenoxacin mesylate [USAN]) with potent antimicrobial activity, against common respiratory pathogens, including resistant strains.

Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is an ATP-competitive, selective, second-generation cell cycle checkpoint kinase 1 (CHK1) inhibitor (IC50<1 nM, Ki: 0.9 nM). It inhibits CHK2 (IC50: 8 nM) and RSK1 (IC50: 9 nM), induces double-stranded DNA breaks and replication mutations, triggers apoptosis, and exhibits potent anti-tumor effects.

Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nM.

Dolasetron Mesylate hydrate (Dalasetron Mesylate Hydrate) , a selective serotonin receptor antagonist, competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.

Tirilazad mesylate hydrate is the hydrated form of Tirilazad mesylate, a nonglucocorticoid, 21-aminosteroid known for inhibiting lipid peroxidation. It is used to mitigate brain or spinal cord injury resulting from trauma, stroke, ischemia, and reperfusion injury and exhibits antiviral activities against nCoV. Additionally, Tirilazad mesylate is noted for its neuroprotective properties in ischemic stroke and is utilized in subarachnoid hemorrhage research [1] [2] [3].